Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

Cited In for PubMed (Select 5436899)

1.

A cancer theory kerfuffle can lead to new lines of research.

Baker SG.

J Natl Cancer Inst. 2014 Dec 20;107(2). pii: dju405. doi: 10.1093/jnci/dju405. Print 2015 Feb.

2.
3.

Pluripotency and its layers of complexity.

Ooi J, Liu P.

Cell Regen (Lond). 2012 Sep 14;1(1):7. doi: 10.1186/2045-9769-1-7. eCollection 2012. Review.

4.

Identification and characterization of germ cell genes expressed in the F9 testicular teratoma stem cell line.

Kwon JT, Jin S, Choi H, Kim J, Jeong J, Kim J, Kim Y, Cho BN, Cho C.

PLoS One. 2014 Aug 25;9(8):e103837. doi: 10.1371/journal.pone.0103837. eCollection 2014.

5.

The Wistar legacy to embryonic stem cell research.

Knowles BB.

Monoclon Antib Immunodiagn Immunother. 2014 Jun;33(3):154-7. doi: 10.1089/mab.2014.0003. Epub 2014 Jun 3. No abstract available.

6.

Origins and implications of pluripotent stem cell variability and heterogeneity.

Cahan P, Daley GQ.

Nat Rev Mol Cell Biol. 2013 Jun;14(6):357-68. doi: 10.1038/nrm3584. Epub 2013 May 15. Review.

7.

A big catch for germ cell tumour research.

Chen KS, Amatruda JF.

PLoS Genet. 2013 Apr;9(4):e1003481. doi: 10.1371/journal.pgen.1003481. Epub 2013 Apr 11. No abstract available.

8.

Establishment of mouse teratocarcinomas stem cells line and screening genes responsible for malignancy.

Liu T, Wang Y, Peng X, Zhang L, Cheng J, Jin H, Wu M, Qian Q.

PLoS One. 2012;7(8):e43955. doi: 10.1371/journal.pone.0043955. Epub 2012 Aug 31.

9.

Pluripotency in the embryo and in culture.

Nichols J, Smith A.

Cold Spring Harb Perspect Biol. 2012 Aug 1;4(8):a008128. doi: 10.1101/cshperspect.a008128. Review.

10.

Tumor stem cells: A new approach for tumor therapy (Review).

Meng M, Zhao XH, Ning Q, Hou L, Xin GH, Liu LF.

Oncol Lett. 2012 Aug;4(2):187-193. Epub 2012 May 25.

11.

Morphogenetic fields in embryogenesis, regeneration, and cancer: non-local control of complex patterning.

Levin M.

Biosystems. 2012 Sep;109(3):243-61. doi: 10.1016/j.biosystems.2012.04.005. Epub 2012 Apr 20. Review.

12.

Embryonic stem cell-derived factors inhibit T effector activation and induce T regulatory cells by suppressing PKC-θ activation.

Mohib K, AlKhamees B, Zein HS, Allan D, Wang L.

PLoS One. 2012;7(3):e32420. doi: 10.1371/journal.pone.0032420. Epub 2012 Mar 7.

13.
14.

The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory.

Soto AM, Sonnenschein C.

Bioessays. 2011 May;33(5):332-40. doi: 10.1002/bies.201100025.

15.

Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression.

Bissell MJ, Hines WC.

Nat Med. 2011 Mar;17(3):320-9. doi: 10.1038/nm.2328. Review.

16.

Loss of Pten causes tumor initiation following differentiation of murine pluripotent stem cells due to failed repression of Nanog.

Lindgren AG, Natsuhara K, Tian E, Vincent JJ, Li X, Jiao J, Wu H, Banerjee U, Clark AT.

PLoS One. 2011 Jan 27;6(1):e16478. doi: 10.1371/journal.pone.0016478.

17.

Present state and future perspectives of using pluripotent stem cells in toxicology research.

Wobus AM, Löser P.

Arch Toxicol. 2011 Feb;85(2):79-117. doi: 10.1007/s00204-010-0641-6. Epub 2011 Jan 12. Review.

18.

The different shades of mammalian pluripotent stem cells.

Kuijk EW, Chuva de Sousa Lopes SM, Geijsen N, Macklon N, Roelen BA.

Hum Reprod Update. 2011 Mar-Apr;17(2):254-71. doi: 10.1093/humupd/dmq035. Epub 2010 Aug 12. Review.

19.

Research on early-stage carcinogenesis: are we approaching paradigm instability?

Baker SG, Cappuccio A, Potter JD.

J Clin Oncol. 2010 Jul 10;28(20):3215-8. doi: 10.1200/JCO.2010.28.5460. Epub 2010 Jun 14. No abstract available.

20.

Differentiating embryonic stem cells pass through 'temporal windows' that mark responsiveness to exogenous and paracrine mesendoderm inducing signals.

Jackson SA, Schiesser J, Stanley EG, Elefanty AG.

PLoS One. 2010 May 19;5(5):e10706. doi: 10.1371/journal.pone.0010706.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk